Securities Class Action Filed Against Grail, Inc. Over Misleading Trial Results
Written by Emily J. Thompson, Senior Investment Analyst
Updated: 1 hour ago
0mins
Source: Globenewswire
- Lawsuit Background: Grail, Inc. faces a securities class action in the Northern District of California, representing all investors who purchased its securities between May 13, 2025, and February 19, 2026, alleging the company concealed significant adverse facts related to the NHS Galleri trial.
- Trial Result Controversy: The complaint claims that Grail failed to demonstrate a statistically significant reduction in Stage III-IV cancers and acknowledged the need for a longer follow-up period to adequately compare study arms, indicating deficiencies in trial design.
- Stock Price Plunge: Following the announcement on February 19, 2026, that the primary endpoint was not met, Grail's stock price plummeted from $101.53 to $50.21, a decline of approximately 50.55%, reflecting strong investor concerns about the company's future.
- Investor Action Call: Gainey McKenna & Egleston urges investors who acquired Grail shares before August 4, 2026, to contact them to act as lead plaintiffs in the class action, thereby protecting their rights and interests.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy GRAL?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on GRAL
Wall Street analysts forecast GRAL stock price to rise
3 Analyst Rating
1 Buy
2 Hold
0 Sell
Moderate Buy
Current: 59.980
Low
38.00
Averages
60.86
High
83.71
Current: 59.980
Low
38.00
Averages
60.86
High
83.71
About GRAL
Grail, Inc. is a healthcare company focused on saving lives and shifting the paradigm in early cancer detection. The Company is focused on alleviating the global burden of cancer by using sequencing, population-scale clinical studies, and machine learning, software, and automation to detect and identify multiple deadly cancer types in earlier stages. Its targeted methylation-based platform can support the continuum of care for screening and precision oncology, including multi-cancer early detection in symptomatic patients, risk stratification, minimal residual disease detection, biomarker subtyping, treatment and recurrence monitoring. Its multi-cancer early detection test, the Galleri test, is a commercially available screening test for early detection of multiple types of cancer. The Galleri test can be used to screen for cancer before a person becomes symptomatic, when cancer may be more easily treated and potentially curable. The Galleri test can indicate the origin of the cancer.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Securities Class Action Filed Against Grail, Inc. Over Misleading Trial Results
- Lawsuit Background: Grail, Inc. faces a securities class action in the Northern District of California, representing all investors who purchased its securities between May 13, 2025, and February 19, 2026, alleging the company concealed significant adverse facts related to the NHS Galleri trial.
- Trial Result Controversy: The complaint claims that Grail failed to demonstrate a statistically significant reduction in Stage III-IV cancers and acknowledged the need for a longer follow-up period to adequately compare study arms, indicating deficiencies in trial design.
- Stock Price Plunge: Following the announcement on February 19, 2026, that the primary endpoint was not met, Grail's stock price plummeted from $101.53 to $50.21, a decline of approximately 50.55%, reflecting strong investor concerns about the company's future.
- Investor Action Call: Gainey McKenna & Egleston urges investors who acquired Grail shares before August 4, 2026, to contact them to act as lead plaintiffs in the class action, thereby protecting their rights and interests.
See More
Shareholder Class Action Filed Against Grail, Inc.
- Lawsuit Background: Grail, Inc. (NASDAQ: GRAL) is facing a shareholder class action lawsuit alleging that the company made false and misleading statements regarding the likelihood of achieving the primary endpoint in its NHS-Galleri trial for Stage III-IV cancers, resulting in investor losses.
- Investor Rights: Shareholders who purchased Grail shares between May 13, 2025, and February 19, 2026, and experienced losses are encouraged to contact Holzer & Holzer law firm to discuss their legal rights and ensure their interests are represented in the lawsuit.
- Deadline for Action: Investors must apply to the court by August 4, 2026, to be appointed as lead plaintiff in the case, which is crucial for representing the interests of affected shareholders and ensuring the class action's validity.
- Law Firm Background: Holzer & Holzer, LLC, established in 2000, has a strong track record in representing shareholders and investors, having recovered hundreds of millions of dollars for victims of fraud and corporate misconduct, showcasing their expertise and influence in securities litigation.
See More
Grail: A Potential Sleeper Stock in Liquid Biopsies
- Massive Market Opportunity: With a market cap of approximately $2.6 billion, Grail focuses on early cancer detection through its Galleri test, which screens for over 50 cancer types, including ovarian, pancreatic, and liver/bile duct cancers that currently lack screening options, highlighting its significant potential in the projected $50 billion liquid biopsy market.
- Significant Clinical Results: At the 2026 American Society of Clinical Oncology Annual Meeting, Grail presented results from the NHS Galleri 2 and Pathfinder 2 trials, demonstrating that Galleri reduced stage IV diagnoses of 12 cancer types by over 20% and detected four times as many cancers when added to standard care, underscoring its effectiveness in early cancer detection.
- FDA Application Progress: Grail submitted its application for full FDA approval of Galleri in January 2026, and if approved, insurers are likely to quickly begin reimbursing the test, further enhancing market acceptance, especially with the support of the Medicare Multi-Cancer Early Detection Screening Coverage Act.
- Investment Risks and Rewards: Despite reporting a net loss of $93.2 million in Q1 2026 and facing competition from Exact Sciences and Guardant Health, Grail's stock could skyrocket if it secures FDA approval and payer reimbursements, making it a focal point for patient investors.
See More
Grail Class Action Lawsuit Initiated Over Stock Misrepresentation
- Lawsuit Background: Robbins Geller Rudman & Dowd LLP has announced a class action lawsuit against Grail, Inc. (NASDAQ: GRAL), representing stock purchasers from May 13, 2025, to February 19, 2026, alleging violations of the Securities Exchange Act of 1934 by its executives.
- False Statement Allegations: The lawsuit claims that Grail falsely asserted its NHS-Galleri trial would significantly reduce late-stage cancer rates, yet the actual results revealed no statistically significant reduction, causing the stock price to plummet over 50% on February 19, 2026.
- Investor Rights: Under the Private Securities Litigation Reform Act of 1995, any investor who purchased Grail stock during the class period can seek to be appointed as lead plaintiff, representing other investors in the lawsuit and selecting their preferred law firm for representation.
- Law Firm Strength: Robbins Geller is a leading law firm in securities fraud and shareholder rights litigation, recovering over $916 million for investors in 2025 alone, and a total of $8.4 billion over the past five years, highlighting its significant strength and influence in the securities class action landscape.
See More
Class Action Lawsuit Filed Against GRAIL, Inc.
- Lawsuit Background: GRAIL, Inc. faces a class action lawsuit for allegedly providing misleading information to investors between May 13, 2025, and February 19, 2026, concealing the true status of its NHS-Galleri trial, which has resulted in significant investor losses.
- Trial Results Disclosure: On February 19, 2026, GRAIL announced that the NHS-Galleri trial did not observe a statistically significant reduction in Stage III-IV cancers, indicating that the trial's design and duration were insufficient to support the achievement of its primary endpoint, directly impacting investor confidence.
- Stock Price Plunge: Following the trial results announcement, GRAIL's stock price plummeted from $101.53 per share on February 19, 2026, to $50.21 per share on February 20, 2026, reflecting a dramatic decline of approximately 50.55%, showcasing the market's extreme pessimism regarding the company's future.
- Investor Action Call: The law firm Levi & Korsinsky urges GRAIL shareholders to apply to be lead plaintiffs by the August 4, 2026 deadline to seek compensation for losses caused by corporate misrepresentations, emphasizing their extensive experience and successful track record in securities litigation.
See More
Grail Shares Surge 31.6% on ASCO Presentation Optimism
- Significant Stock Surge: Grail's shares surged by 31.6% in May, reaching $5.42 per share, as market optimism grew around its presentation at the American Society of Clinical Oncology (ASCO) meeting, which is expected to bolster the case for FDA approval of the Galleri test and enhance insurance coverage.
- Clinical Trial Setbacks: Despite the Galleri test's failure to meet primary endpoints in a three-year trial conducted by the NHS, management highlighted a substantial increase in early-stage cancers among 12 specified deadly cancer types, indicating potential clinical significance and a favorable trend in detection rates.
- FDA Collaboration Strategy: Grail plans to continue working with the FDA to secure approval for the Galleri test and present detailed results from the NHS trial at ASCO, aiming to strengthen the case for FDA approval and persuade insurers to cover the test.
- Future Prospects: Management aims to obtain NHS approval for follow-up trials by next summer, emphasizing the critical importance of early-stage cancer diagnosis in improving survival rates, which could further enhance market acceptance of the Galleri test.
See More
Securities Class Action Filed Against Grail, Inc. Over Misleading Trial Results
- Lawsuit Background: Grail, Inc. faces a securities class action in the Northern District of California, representing all investors who purchased its securities between May 13, 2025, and February 19, 2026, alleging the company concealed significant adverse facts related to the NHS Galleri trial.
- Trial Result Controversy: The complaint claims that Grail failed to demonstrate a statistically significant reduction in Stage III-IV cancers and acknowledged the need for a longer follow-up period to adequately compare study arms, indicating deficiencies in trial design.
- Stock Price Plunge: Following the announcement on February 19, 2026, that the primary endpoint was not met, Grail's stock price plummeted from $101.53 to $50.21, a decline of approximately 50.55%, reflecting strong investor concerns about the company's future.
- Investor Action Call: Gainey McKenna & Egleston urges investors who acquired Grail shares before August 4, 2026, to contact them to act as lead plaintiffs in the class action, thereby protecting their rights and interests.
See More
Shareholder Class Action Filed Against Grail, Inc.
- Lawsuit Background: Grail, Inc. (NASDAQ: GRAL) is facing a shareholder class action lawsuit alleging that the company made false and misleading statements regarding the likelihood of achieving the primary endpoint in its NHS-Galleri trial for Stage III-IV cancers, resulting in investor losses.
- Investor Rights: Shareholders who purchased Grail shares between May 13, 2025, and February 19, 2026, and experienced losses are encouraged to contact Holzer & Holzer law firm to discuss their legal rights and ensure their interests are represented in the lawsuit.
- Deadline for Action: Investors must apply to the court by August 4, 2026, to be appointed as lead plaintiff in the case, which is crucial for representing the interests of affected shareholders and ensuring the class action's validity.
- Law Firm Background: Holzer & Holzer, LLC, established in 2000, has a strong track record in representing shareholders and investors, having recovered hundreds of millions of dollars for victims of fraud and corporate misconduct, showcasing their expertise and influence in securities litigation.
See More
Grail: A Potential Sleeper Stock in Liquid Biopsies
- Massive Market Opportunity: With a market cap of approximately $2.6 billion, Grail focuses on early cancer detection through its Galleri test, which screens for over 50 cancer types, including ovarian, pancreatic, and liver/bile duct cancers that currently lack screening options, highlighting its significant potential in the projected $50 billion liquid biopsy market.
- Significant Clinical Results: At the 2026 American Society of Clinical Oncology Annual Meeting, Grail presented results from the NHS Galleri 2 and Pathfinder 2 trials, demonstrating that Galleri reduced stage IV diagnoses of 12 cancer types by over 20% and detected four times as many cancers when added to standard care, underscoring its effectiveness in early cancer detection.
- FDA Application Progress: Grail submitted its application for full FDA approval of Galleri in January 2026, and if approved, insurers are likely to quickly begin reimbursing the test, further enhancing market acceptance, especially with the support of the Medicare Multi-Cancer Early Detection Screening Coverage Act.
- Investment Risks and Rewards: Despite reporting a net loss of $93.2 million in Q1 2026 and facing competition from Exact Sciences and Guardant Health, Grail's stock could skyrocket if it secures FDA approval and payer reimbursements, making it a focal point for patient investors.
See More
Grail Class Action Lawsuit Initiated Over Stock Misrepresentation
- Lawsuit Background: Robbins Geller Rudman & Dowd LLP has announced a class action lawsuit against Grail, Inc. (NASDAQ: GRAL), representing stock purchasers from May 13, 2025, to February 19, 2026, alleging violations of the Securities Exchange Act of 1934 by its executives.
- False Statement Allegations: The lawsuit claims that Grail falsely asserted its NHS-Galleri trial would significantly reduce late-stage cancer rates, yet the actual results revealed no statistically significant reduction, causing the stock price to plummet over 50% on February 19, 2026.
- Investor Rights: Under the Private Securities Litigation Reform Act of 1995, any investor who purchased Grail stock during the class period can seek to be appointed as lead plaintiff, representing other investors in the lawsuit and selecting their preferred law firm for representation.
- Law Firm Strength: Robbins Geller is a leading law firm in securities fraud and shareholder rights litigation, recovering over $916 million for investors in 2025 alone, and a total of $8.4 billion over the past five years, highlighting its significant strength and influence in the securities class action landscape.
See More
Class Action Lawsuit Filed Against GRAIL, Inc.
- Lawsuit Background: GRAIL, Inc. faces a class action lawsuit for allegedly providing misleading information to investors between May 13, 2025, and February 19, 2026, concealing the true status of its NHS-Galleri trial, which has resulted in significant investor losses.
- Trial Results Disclosure: On February 19, 2026, GRAIL announced that the NHS-Galleri trial did not observe a statistically significant reduction in Stage III-IV cancers, indicating that the trial's design and duration were insufficient to support the achievement of its primary endpoint, directly impacting investor confidence.
- Stock Price Plunge: Following the trial results announcement, GRAIL's stock price plummeted from $101.53 per share on February 19, 2026, to $50.21 per share on February 20, 2026, reflecting a dramatic decline of approximately 50.55%, showcasing the market's extreme pessimism regarding the company's future.
- Investor Action Call: The law firm Levi & Korsinsky urges GRAIL shareholders to apply to be lead plaintiffs by the August 4, 2026 deadline to seek compensation for losses caused by corporate misrepresentations, emphasizing their extensive experience and successful track record in securities litigation.
See More
Grail Shares Surge 31.6% on ASCO Presentation Optimism
- Significant Stock Surge: Grail's shares surged by 31.6% in May, reaching $5.42 per share, as market optimism grew around its presentation at the American Society of Clinical Oncology (ASCO) meeting, which is expected to bolster the case for FDA approval of the Galleri test and enhance insurance coverage.
- Clinical Trial Setbacks: Despite the Galleri test's failure to meet primary endpoints in a three-year trial conducted by the NHS, management highlighted a substantial increase in early-stage cancers among 12 specified deadly cancer types, indicating potential clinical significance and a favorable trend in detection rates.
- FDA Collaboration Strategy: Grail plans to continue working with the FDA to secure approval for the Galleri test and present detailed results from the NHS trial at ASCO, aiming to strengthen the case for FDA approval and persuade insurers to cover the test.
- Future Prospects: Management aims to obtain NHS approval for follow-up trials by next summer, emphasizing the critical importance of early-stage cancer diagnosis in improving survival rates, which could further enhance market acceptance of the Galleri test.
See More
